SALT LAKE CITY — In this video, Jay Chhablani, MD, discusses findings presented at the ARVO meeting from a phase 2b study evaluating suprachoroidal axitinib for neovascular age-related macular degeneration.
The trial enrolled 60 previously treated patients with stable vision and compared suprachoroidal axitinib (Clearside Biomedical) with intravitreal aflibercept 2 mg (Regeneron). Visual acuity and retinal thickness were comparable between the two treatments, according to Chhablani, professor of ophthalmology at University of Pittsburgh School of Medicine. Notably, 67% of patients in the